GHENT, Belgium, Feb. 18, 2016 -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will announce its full year results for 2015 on Thursday 25 February 2016 at 7.00 am CET.
The Ablynx management team will host a conference call and webcast during which the full year results for 2015 will be presented, followed by a Q&A session. This event will be held on Thursday 25 February 2016 at 4.00 pm CET/10.00 am EST.
The conference call will be webcast live and may be accessed by clicking here. If you would like to participate in the Q&A session, please dial +32(0)2 404 06 62 and use confirmation code 4640794. Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under http://www.ablynx.com/news/events-presentations/.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact Ablynx: Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Marieke Vermeersch Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: [email protected]
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: [email protected]
press release in pd format http://hugin.info/137912/R/1986956/729119.pdf
HUG#1986956


Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched
Nissan Halts Electric Qashqai Development Amid EV Market Challenges
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 



